-
Share
3,318 Posts.
780
20/05/24
14:44
Share
It certainly doesn’t seem like any of the long-touted potential partners are stepping up to the plate to licence any of the 3 internal DEP drugs.
Perhaps Starpharma (if they genuinely back their own science) will pick the best candidate to prioritise funds and take into Phase 3.
A $40m capital raising (500m shares issued at 8 cents each) would probably provide enough capital for a small and modest Phase 3 trial.
Do they believe in their own science though?
-
